Publications by authors named "J K Willmann"
Introduction: Reirradiation has gained increasing interest, as advances in systemic therapy increase the survival of patients with cancer, and modern radiation techniques allow more precise treatments. However, high-quality prospective evidence on the safety and efficacy of reirradiation to guide clinical practice remains scarce. This systematic review evaluates ongoing prospective studies on reirradiation to identify research gaps and priorities.
View Article and Find Full Text PDFArticle Synopsis
- A subgroup of patients with oligometastatic cancer may benefit from local treatment of all cancer lesions to achieve longer disease-free survival, especially when brain metastases are involved.
- An analysis of 7,000 PET scans identified 106 patients with both extracranial oligometastases and brain metastases, finding that brain involvement significantly impacted disease classification and treatment outcomes.
- Patients with oligometastasic disease had a median survival of 28 months compared to 10 months for polymetastatic patients, suggesting that brain metastases should not automatically exclude individuals from clinical trials.
With the emergence of high-precision radiotherapy technologies such as stereotactic ablative radiotherapy (SABR), MR guided brachytherapy, image guided intensity modulated photon and proton radiotherapy and most recently daily adaptive radiotherapy, reirradiation is increasingly recognized as a viable treatment option for many patients. This includes those with recurrent, metastatic or new malignancies post initial radiotherapy. The primary challenge in reirradiation lies in balancing tumor control against the risk of severe toxicity from cumulative radiation doses to previously irradiated normal tissue.
View Article and Find Full Text PDFAims: Multidisciplinary tumor boards (MDTs) are an integral part of ensuring high-quality, evidence-based and personalized cancer care. In this study, we aimed to evaluate the adherence to and implementation of MDT recommendations in patients with oligometastatic disease (OMD).
Methods: We screened all oncologic positron emission tomography (PET) scans conducted at a single comprehensive cancer center in 2020.
Background: The treatment options for patients with progressive malignant tumors despite primary radiotherapy are often limited. In selected cases, re-irradiation can be offered. This article concerns the selection criteria and results of re-irradiation for certain types of cancer.
View Article and Find Full Text PDF